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On the 20th June, 2014 the National Health and Medical Research Council’s Centre for Research
Excellence in Population Health ‘‘Immunisation in under Studied and Special Risk Populations”, in collab-
oration with the Public Health Association of Australia, hosted a workshop ‘‘Equity in disease prevention:
vaccines for the older adults”. The workshop featured international and national speakers on ageing and
vaccinology. The workshop was attended by health service providers, stakeholders in immunisation, age-
ing, primary care, researchers, government and non-government organisations, community representa-
tives, and advocacy groups. The aims of the workshop were to: provide an update on the latest
evidence around immunisation for the older adults; address barriers for prevention of infection in the
older adults; and identify immunisation needs of these groups and provide recommendations to inform
policy.
There is a gap in immunisation coverage of funded vaccines between adults and infants. The workshop
reviewed provider misconceptions, lack of Randomised Control Trials (RCT) and cost-effectiveness data in
the frail elderly, loss of autonomy, value judgements and ageism in health care and the need for an adult
vaccination register. Workshop recommendations included recognising the right of elderly people to pre-
vention, the need for promotion in the community and amongst healthcare workers of the high burden of
vaccine preventable diseases and the need to achieve high levels of vaccination coverage, in older adults
and in health workers involved in their care. Research into new vaccine strategies for older adults which
address poor coverage, provider attitudes and immunosenescence is a priority. A well designed national
register for tracking vaccinations in older adults is a vital and basic requirement for a successful adult
immunisation program. Eliminating financial barriers, by addressing inequities in the mechanisms for
funding and subsidising vaccines for the older adults compared to those for children, is important to
improve equity of access and vaccination coverage. Vaccination coverage rates should be included in
quality indicators of care in residential aged care for older adults. Vaccination is key to healthy ageing,
and there is a need to focus on reducing the immunisation gap between adults and children.online@
y.edu.au
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The proportion of adults that are over the age of 60 in Australia
is expected to increase from the current 14% to 25% in 2056. This
has implications for the future workforce age distribution and
the quality of life of the elderly. The definition of quality of life
for the older adult is derived from the World Health Organization’s
definition of health as a state of complete physical, mental and
social wellbeing [1], with the emphasis on physical health and
functional ability [2].
There are more people aged 85 years and older in aged care
facilities now [3] with the average length of stay in an aged care
facility being 2.8 years, an 11% increase over the last decade. There-
fore the wellbeing of people in aged care facilities is becoming an
increasingly important issue [3,4].
In 2010, infectious diseases were leading contributors to the
burden of disease in people aged 60 years and older [5]. Influenza,
pneumococcus and varicella zoster are vaccine preventable dis-
eases but remain a significant cause of morbidity and mortality
among older adult population [4]. Older adults are at higher risk
of contracting many vaccine preventable diseases, and do not
respond well to treatment. They are therefore at higher risk of suf-
fering serious complications, disability and death from those
diseases.
This report describes the presentations and discussions during
the panel session on ‘‘How good is good enough for the elderly?” a
title which reflects the lower immunogenicity of vaccines in older
adults due to immunosenescence, negative provider attitudes to
elderly vaccination, and the lower uptake of vaccines in this age
group. The workshop was attended by Australian health service
providers, stakeholders in immunisation, ageing, primary care,
researchers, government and non-government organisations, com-
munity representatives, and advocacy groups. The aims of the
workshop were to: provide an update on the latest evidence
around immunisation for the elderly; address barriers for preven-
tion of infection in the elderly; and identify immunisation needs of
these groups and provide recommendations to inform policy and
improve disease prevention in older Australians.2. Impact of vaccine preventable diseases on quality of life
Maintaining function is a key ingredient to enablement, quality
of life and the prevention of the deleterious effects of immobility
and inactivity for older adults [6]. Preventable illnesses such as,
shingles, pneumococcal disease, influenza and pertussis and their
sequelae can result in death or reduced activity and function,
which may push people over a threshold from living independently
into permanent disability.
Participation and social inclusiveness are very important for the
overall wellbeing of elderly Australians [7]. Social isolation is
another result of acute illness and/or the resulting disability, which
can be a risk factor for other diseases and disability.
There are substantial impacts on nursing homes residents, caus-
ing morbidity, disability, dependency and reducing quality of life.
Once older adults in aged care facilities become disabled they
become a much greater burden to staff, which further reduces
social connection and quality of life [8]. Other impacts are on the
cost of care at emergency departments and inpatient wards, and
the possibility of nosocomial transmission of preventable infec-
tious diseases to and from the older adults. Nursing home out-
breaks have major health and economic consequences [9].
Disease prevention is a means of promoting positive ageing, pre-
venting suffering and improving quality of life. It is possible the
benefit of vaccination in improving quality of life for the elderly
is not valued as highly as gaining years of life [3,4].Another reason for the under-use of vaccines is their lower
effectiveness in older adults compared to younger populations.
However, there is a heavier burden of many vaccine preventable
diseases in this group, compared to younger populations. Therefore
there may still be substantial overall public health benefit to be
gained from the use of vaccines when the burden of disease is high
[10]. In fact, vaccines have higher efficacy compared to many other
widely used preventative public health strategies for the older
adults such as statins and anti-hypertensive treatments, and it
may be more appropriate to compare adult vaccination with other
accepted adult preventive strategies than with infant vaccination
[11].
In public health, many accepted interventions such as statins
and smoking cessation have preventive efficacy of less than 30%
[12,13]. Yet health practitioners often dismiss as unworthy vacci-
nes with efficacy less than 80%. Therefore a paradigm shift is
required to view vaccines in the elderly in terms of burden of dis-
ease and efficacy, not efficacy alone.
2.1. Shingles
Shingles has a large impact on the quality of life of older adults,
much of which is not captured in standard cost effective analysis of
vaccines [14].
At least 10–20% of the older adults who develop shingles will
develop post herpetic neuralgia (PHN). The mean duration of
PHN is 3.3 years [15]. A nationwide survey of the impact of shin-
gles on quality of life of seniors found that their ability to work
was adversely affected in 32% of case [7], and participation in social
and community activities was impacted in around half of cases.
Most shingles patients who report with post herpetic neuralgia
(PHN) require substantial assistance from family members.
Vaccination is the only intervention that has proven to be effec-
tive in prevention of shingles [15,16]. A single dose of zoster vac-
cine is recommended for adults 50 years of age and older who
have not received a dose of zoster vaccine. A study involving par-
ticipants aged >60 years showed an overall reduction in the popu-
lation incidence of herpes zoster of 51.3% and the incidence of PHN
by 66.5% [16]. (Note: On 9 May 2015 the Australian Government
announced funding for a single dose of zoster vaccine for those
aged 70–79 years [17].)
2.2. Pneumococcal disease
The effectiveness of pneumococcal vaccine is particularly
important in nursing home residents, the majority of whom are
frail older adults and have co-morbidities. There is scarce research
on the effectiveness of pneumococcal vaccines in nursing homes. A
study in Hong Kong [18], showed effectiveness of 40% for pneumo-
coccal vaccines among older adults in nursing homes. Other stud-
ies [19] large randomised controlled trial (CAPiTA) examined the
efficacy of PCV13 in preventing invasive pneumococcal disease
the population 65 years of age and older found a vaccine efficacy
of 75% against invasive disease and 48.5% against pneumonia,
although this was not in nursing home residents [20]. The 13-
valent conjugate vaccine [20] is currently licensed for use in people
aged P65 years and it is funded under the NIP.
2.3. Influenza
The majority of deaths caused by influenza occur in people aged
65 years and over. The frail older adults suffering from chronic con-
ditions and residents of aged care facilities are at higher risk of out-
breaks. A meta-analysis of 35 test-negative case-control studies
found that influenza vaccination of the older adults was associated
with a significant reduction in the risk of hospitalization for pneu-
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cine show effectiveness in prevention of influenza for persons aged
over 50 years, and reductions in hospitalisations from influenza
and pneumonia and all-cause mortality in adults P65 years of
age [21]. Influenza vaccine is also associated with a reduction in
risk of myocardial infarction, which is an additional benefit in older
adults [11,22]. Annual influenza vaccination is recommended and
funded for people 65 years and older and residents of residential
aged care facilities [23]. Influenza vaccination is also recom-
mended for all health care providers, people who work in nursing
homes and long term care facilities. However, the vaccine is not
funded nationally for health care workers and coverage remains
low [24]. Australia has not yet achieved influenza vaccine coverage
goals for adults aged 60 years and older which were set by the
World Health Organization (WHO) as 50% by 2006 and 75% by
2010 [25].2.4. Pertussis
Pertussis notification rates in Australia 1995–2010 have
increased significantly in older age groups [26]. Nursing home out-
breaks of pertussis have also been documented. There is significant
morbidity associated with pertussis infection in infants <6 months
of age and household contact is often the source of infection in
infants [23]. One third of working mothers have a grandparent pro-
viding childcare for children under school age. Unvaccinated carers
put infants at risk of severe disease and death. Pertussis vaccine is
recommended for adults who are in contact with infants and
others at increased risk from pertussis. However, this recommen-
dation is not funded under the NIP [23]. It has traditionally been
believed that pertussis is only fatal in infants, but there are docu-
mented deaths from pertussis in elderly Australians in recent
years, highlighting the risk to the older adults from this infection
[10].3. Vaccination schedule for adults – National Immunisation
Program (NIP)
Guidelines of Australia and New Zealand society of geriatric
medicine have recommended vaccination for influenza, pneumo-
coccal disease, tetanus and shingles, and for those who are regu-
larly in contact with children, pertussis. At the time of the
workshop, only influenza and pneumococcal polysaccharide vacci-
nes were funded under the National Immunisation Program (NIP),6
whereas for children vaccines are funded for 13 diseases and there
are no vaccines that are recommended but unfunded. The cost of
unsubsidized vaccines can be high and unaffordable for older adults
and pensioners.
One of the key issues is that infant vaccination is applicable to a
single birth cohort per year, and is therefore less costly to initiate
than a recommendation for all adults >65 years, which represents
numerous birth cohorts and a much larger initial investment in
funding. For example, in Australia, approximately 250,000 children
are born each year, so that a single birth cohort represents 1% of
the population - in contrast, there are approximately 3,300,000
people >65 years, representing 15% of the population [27]. There-
fore initial government investment for a new adult vaccination
program recommended for everyone aged >65 years would be 15
times greater than for a new infant program, for a vaccine of the
same price. Potential strategies to overcome this problem include6 Subsequently, on 9 May 2015, the Australian Government announced funding for
Varicella Zoster (shingles) vaccine for all Australians aged 70–79 years. (ref http://
www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-
yr2015-ley048.htm).staged vaccine programs, which may commence with a narrower
age group initially and then expand to wider age groups.
Vaccines are provided free once they are included on the
National immunisation program. These decisions are made by
the Pharmaceutical Benefits Advisory Committee (PBAC), where
the mechanisms are better suited to drugs and products serving
young people [28]. Discounting heavily biases against vaccines
compared to drugs, as benefits accrue in the distant future com-
pared to the immediate benefit of drugs. Current PBAC considera-
tions of persistence of immunity and life expectancy favour
vaccines used in children, and substantial potential improvements
in quality of life in older adults are undervalued. If a vaccine is
shown to be effective in the elderly but does not satisfy PBAC
requirements, there could be alternative mechanisms to subsidise
it to improve access by the elderly.
4. Challenges of adult vaccination
There are significant barriers to vaccination of older adults that
are not present for younger age groups. These include access to
care, mobility, multiple providers, lack of provider confidence in
adult vaccination, lack of clinical trial data in the frail elderly,
and a paediatric immunisation culture [10]. Vaccination rates for
funded adult vaccinations (50–70%) are much lower than they
are for funded childhood vaccines (>90%), which highlight the chal-
lenge of adult vaccination. In the absence of an immunisation reg-
ister that includes older adults, or a universal health record, it is
often difficult to track which vaccinations have been given. Older
adults may have multiple vaccines providers, which makes vacci-
nation tracking more difficult. The introduction of a whole of life
immunisation register in 2016 will overcome these difficulties. A
major barrier is the fact that many health providers do not have
confidence in the effectiveness of vaccinating older adults. This is
compounded by the lack of vaccine clinical trials which include
frail elderly [29,30], resulting in a scarce evidence base. As the pop-
ulation ages, it is important to increase the evidence-base by
including frail elderly in clinical trials, or the lack of provider con-
fidence in vaccines will be difficult to change. Newer data show
that novel adjuvants and other innovations can overcome
immunosenescence in the elderly [31]. The focus of vaccine
research should continue to be on improving immunogenicity in
the frail elderly, and results of such research need to be communi-
cated to health providers to drive change in immunisation practice
and improve uptake.
4.1. Immunological changes in aged population
The ageing process includes numerous immunological changes.
Factors that lead to immunosenescence are complex, involving a
combination of frailty, disability, co-morbidity and a predictable
age-related immunological decline after the age of 50 [10], a wide
range of defects in cellular and humoral immunity occur with age-
ing, and accelerates with increasing age. Immunosenescence may
affect young age groups as well as old, however cell mediated
immunity wanes exponentially after the age of 50 years [32], and
waning immunity makes vaccines less effective in the elderly.
However, novel approaches to vaccination can improve
immune responses in older adults, – for example, a phase 3 trial
of an inactivated herpes zoster vaccine have shown 97% efficacy
in the older adults, which surpasses the efficacy of many childhood
vaccines [31]. Use of a higher dose inactivated influenza vaccine
has been found to be significantly more effective in prevention of
influenza than standard-dose vaccine [33]. Further, a schedule of
7-Valent Pneumococcal Conjugate Vaccine (PCV7) - 23-valent
pneumococcal polysaccharide vaccine (23vPPV) prevents waning
of antibody more than either vaccine used alone, suggesting that
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[34]. One study [35] shows that conjugated pneumococcal vaccines
had significant impact on prevention of invasive pneumococcal
disease (IPD) in vaccinated and non-vaccinated elderly, young
adults and younger children. In another study [36] herd immunity
was demonstrated in adults following use of the trivalent- live
attenuated influenza vaccine (CAIV-T) in children, which resulted
in an indirect protection of 8–18% against medically attended acute
respiratory illness in adultsP35 years of age. Vaccinating younger
age groups to protect the elderly through herd immunity effects
could be considered in some situations. The workshop recom-
mended the development and support of novel vaccine technolo-
gies and strategies to overcome the reduced efficacy which
results from immunosenescence and other age associated defects
in vaccine response.
4.2. Absence of a whole of life register for adult vaccines
Computerized clinical and immunisation registers are useful
tools for providing detailed information about vaccination cover-
age in the population [37]. A whole of life approach to vaccination
is needed and this should be equally accessible to all ages.
A lack of access to immunisation records has major impact on
vaccination rates, especially in adults who are a mobile population,
often with multiple health providers. Patient recall has been the
main method of getting information on vaccine history among
older adults, and is known to be inaccurate [38]. This is particularly
difficult where older adults visit different General Practitioners
(GPs) and may have several different hospital admissions [39]. This
will have an impact on coverage, where for example GPs are reluc-
tant to give pneumococcal vaccines due to incomplete or absent
immunisation records the possibility that a patient might have
received it previously. A register will enable timely reminders for
adult vaccination.
A European study found that countries which had developed
universal mechanisms to record and monitor uptake of vaccines,
and clear national objectives to increase older adults’ vaccine
uptake, had higher vaccine uptake compared to the countries
which didn’t [40]. Interventions facilitated by registers, such as
sending personal letters offering free vaccination, showed on aver-
age higher vaccine coverage among older adults than settings with
less developed vaccine management systems [39]. The presence of
additional policy elements such as giving incentives to health care
workers, vaccination reimbursement systems and awareness cam-
paigns leads to increases in vaccine coverage among older adults.
The Northern Territory Immunisation Register (NTIR) contains
records of vaccines administered to adults and children in the
Northern Territory since 1991. Immunisation records from child-
hood vaccines programs, school-based vaccination programs, adult
vaccines and travel vaccines are all recorded on the register. This is
an example of a valuable and cost effective mechanism that can be
used countrywide. In the absence of a register, a pocket-sized
immunisation card with immunisation history recorded on it could
be kept in an easy to reach place such as with the pension card, to
allow easy access of immunisation records for older adults. The
workshop recommended investigating a range of possible ways
of keeping a universal record of immunisation, such as an adult
immunisation register, Facebook/health book (healthy.me) and
electronic health records. A whole of life register will commence
in 2016 in Australia. We recommend that GP’s be able to access
the immunisation register to check vaccination status of adults
and that it record country of birth, parents’ country of birth, refu-
gee status, Indigenous status, and residence in aged care facilities
as flags for risks of under immunisation or infection. ‘Visiting
Friends and Relatives’ travel is a major source of imported infec-
tions and may affect second generation adult migrants [41]. Forrecording of vaccination, data recording which distinguishes
between polysaccharide vs conjugate pneumococcal vaccine and
trivalent vs quadrivalent influenza vaccine is needed. Reminder
systems for adult vaccination should be built into the register.
4.3. Health care provider attitudes to adult vaccination
Doctors’ recommendation to vaccinate plays a significant role in
the decision to be vaccinated, even in people with negative percep-
tions of vaccination [42]. Healthcare workers’ attitudes to vaccina-
tion of older adults and their own vaccination status are important
factors influencing recommendation of vaccination. Firstly, a lack
of awareness about adult vaccines by health care professionals
and the public is a major barrier to adequate vaccination rates in
elderly Australians. In general, doctors and providers are less con-
vinced about vaccines for the older adults than they are for chil-
dren [10]. Adult vaccination may be a low priority during GP
visits, when multiple acute medical conditions take precedence.
Institutional protocols to identify patients needing vaccination
and ensuring vaccination can improve uptake [43,44]. Health care
workers are at risk of acquiring infectious diseases, and vaccines
are effective in preventing transmission between health care work-
ers and their patients in aged care facilities [45]. However, staff
vaccination rates are still low, especially among staff working in
aged care facilities. Recommending vaccination to employees, pro-
viding free vaccination, on site, and requiring vaccination as a con-
dition for being employed, are associated with higher employee
influenza vaccination rates [46].
There is evidence that text messaging, accessing immunisation
campaign websites, using patient-held web-based portals and
computerized reminders increase immunisation coverage rates,
especially when recommended by health care providers [46]. The
workshop recommended mandatory vaccination for staff and the
maintenance of staff vaccination records. Aged care facilities
should be a particular focus, and be required to have a vaccination
policy linked to accreditation, which recommends staff vaccination
including influenza, preferably provided free in the workplace, and
accompanying education campaigns. Advanced care planning is
becoming more common and more systemised, however vaccina-
tion is rarely included in advance care plans.
4.4. Lack of vaccine awareness among public and older adults
The senior population and the community in general do not
fully appreciate the risks of adult vaccine-preventable diseases,
the complications that may arise from vaccine preventable dis-
eases, the benefit of vaccination, including prevention of cancer
and myocardial infarction [11,47]. There are misconceptions and
myths around flu vaccine, for example beliefs that influenza vac-
cine causes flu, which causes unwillingness among older adults
to be vaccinated. Immunisation information resources and cam-
paigns usually target children, and there is less promotional mate-
rial for adult vaccination.
4.5. Scarcity of data
One major barrier for the PBAC to approve vaccines for older
adults is a lack of data. There is insufficient research on immunisa-
tion among older adults due to the systematic exclusion of frail
elderly and other minority groups from randomised control trials
(RCTs) [30]. Reasons for excluding the frail elderly from participa-
tion in RCTs include multiple medical conditions, polypharmacy,
dementia and decreased cognition, high mortality and high attri-
tion rates affecting study power, longer recruitment processes
(guardian consent), altered body-mass index, potential lower renal
and hepatic clearance of drugs and risk of adverse events, isolation,
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poorer immunological responses [10]. Research on influenza vac-
cine, the most widely used vaccine in older adults, is more complex
than other vaccines because it is an annual vaccine, and efficacy is
affected by the degree of match with circulating strains. Therefore
influenza vaccine trials should be run over multiple seasons to
account for variability in circulating strains. There are few RTCs
done on influenza vaccine as it is widely funded already, and con-
sequently there are many observational studies, with accompany-
ing biases. These difficulties lead to a vicious cycle of lack of
evidence, lack of recommendation and lack of protection from vac-
cine preventable diseases. Studies of efficacy/effectiveness specific
to the vaccine strains are needed. Even if influenza vaccine
effectiveness against infection is found to be low, it may be more
effective against severe disease. There are also substantial indirect
costs of infections, which are not considered by PBAC, and can be
difficult to measure. These include effects of vaccine preventable
diseases on quality of life, such as being put in aged care as a result
of herpes zoster, and costs to carers if increased home care is
required. More evidence is needed on these indirect benefits of
vaccines in older adults.
5. Ethical challenges and ageism
The health care offered to older people is subject to a variety of
ethical concerns. Factors associated with this are the increased fre-
quency of illness including cognitive impairment in older people,
assumptions of incapacity, diminished quality of life and impend-
ing mortality, and the increased vulnerability and loss of autonomy
of the older person when acutely ill. Whilst infants, who also lack
autonomy, have a parent as their advocate, elderly people may
have no advocate and therefore be more vulnerable. Among clini-
cians, primary care physicians are best situated to assist elderly
patients in exercising their autonomy in matters concerning health
care decisions [48]. Some sub groups of older people are particu-
larly at risk of being regarded as unworthy of preventive interven-
tions, such as persons with dementia or people living in aged care
facilities. Research has shown that the demented frail older people
are less likely to be vaccinated than non-demented. In someTable 1
Keyworkshop recommendations.
 Create a universal record, or register, of immunisation in older adults – investigate
such as GP software, Medicare records, aged care facilities and primary care. The
Vaccination Administration System (VIVAS) in Queensland and the Monash mod
It is noted that a whole of life register was announced in May 2015. It is importan
status be well recorded, and that GPs be able to check immunisation status of pa
 Country of birth, parents country of birth, residence in aged care facility, Indigeno
nisation Register to enable GP’s identify risk of under immunisation. For recordin
pneumococcal vaccine and trivalent vs quadrivalent influenza vaccine is needed.
age-based health promotion messages and vaccination reminders similar to thos
 In conjunction with the above point, improve record keeping for adult immunisatio
nisation record for older adults and linking seniors’ cards to vaccination records
 Achieve and maintain high coverage by addressing two key issues: low coverage o
barriers to access for unfunded vaccines. Develop a separate set of guidelines and
 Reduce financial barriers
 Address the imbalance of educational resources on immunisation by developing r
coccal and shingles vaccines, which have lower vaccination rates compared to in
 Include vaccination as a key component of advanced care planning for the older
 Include vaccination rates as a key quality indicator for health care of the older ad
 Support informed and respectful discussions between clinicians, patients and fami
the context of advanced care planning. It is important to acknowledge and reflec
 Mandatory, free, immunisation for staff of aged care facilities, and linking vaccina
 Ongoing, sustainable education for health care providers. The workshop also rec
increasing of vaccination rates, through various media channels
 Encourage research funders to support more research on new vaccine strategies f
vaccine response, such as higher doses, vaccine combinations, the use of boosterssettings older seniors >80 years are less likely to be vaccinated
than those under 80 [42].
While the treatment offered to individuals may not be equal,
treating individuals as equal is required for ethical resource alloca-
tion [49]. However, older people are not always considered of
equal worth in our society, and ageist assumptions are entrenched.
Research has found that health care workers treat older patients
differently to younger patients, and often they are given lower pri-
ority which may result in withholding treatment, prevention or
information [50]. Other studies [51,52] have shown that there is
under-provision of community care and comprehensive
approaches to health care for older adults, as well as over-
utilisation of certain specialised services.
Elderly people are vulnerable to increased adverse events
including errors of omission (that is where the required care is
not provided) and errors of commission (where they experience
harm based on a clinical intervention) [53]. Omission (such as fail-
ure to vaccinate) occurs where the individual’s age rather than
their (potential or actual) underlying condition influences diagnos-
tic decision making, particularly if cognitive impairment is present
[54].
Older persons have a right to autonomy, self-determination and
informed choice about vaccines. Informed choice can only be made
if older people are given access to information that affects their
health. Decisions should arise from dialogue and avoid clinicians’
assumptions about what their older patients may want or feel is
appropriate. Common clinical situations such as acute delirium
(often a result of acute infection) in the older person with other-
wise normal cognition can lead to temporary loss of autonomy,
during which time health care decisions will be made for them.
Decisions about vaccination should be taken in the context of
exploring goals of care with the patient and aligning current or
future decisions with these goals ideally in periods of stable health
[55].
Patients without an advocate in health care are considered to be
especially vulnerable. Vulnerability has been defined as suscepti-
bility to any kind of harm, whether physical, moral or spiritual,
at the hands of an agent or agency, a factor which needs to be rec-
ognized and negotiated in health care transactions [56].data linkage mechanisms to link adult immunisation data from various sources
Northern Territory Immunisation Register (NTIR), Vaccination Information and
el of immunisation service for high risk patients could be looked at as models.
t that variables such as country of birth, parents’ country of birth and Indigenous
tients
us status and refugee status be included in the new announced Australia Immu-
g of vaccination, the ability to distinguish between polysaccharide vs conjugate
Reminder systems for adult vaccination should be built into the register. Create
e for bowel cancer screening
n, such as keeping records in residential aged care, creating a grey book of immu-
f vaccines which are funded under the National Immunisation program (NIP) and
alternative mechanisms for the PBAC to subsidise vaccines for older adults
esources targeted at adults. In particular, education is needed around pneumo-
fluenza vaccine
adults
ults and aged care facilities
lies of the benefits and burdens of preventive health measures for older people in
t on ageism and value judgements in health care
tion of staff and residents with accreditation
ommended increasing advocacy for the wellbeing of the older adults, including
or the older adults to address immunosenescence and age associated defects in
, adjuvants, novel technologies and protection through herd immunity
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Australia’s Indigenous people, Aboriginal and Torres Strait
Islanders, die at a younger age compared to the rest of population,
however trends show a steady increase in the older Indigenous
population and the number is projected to increase further in next
two decades [57]. Aboriginals aged 50–55 years are entitled to
health checks which includes reviewing of immunisation records
[23]. There is better uptake of influenza and pneumococcal vacci-
nes among the Indigenous population compared to the rest of older
adults population [58]. The workshop saw that when Aboriginal
people are engaged with their local communities’ health services,
they tend to seek help and health care.
The Aboriginal Community Controlled Health Services play an
important role in ensuring older adults are cared for and vacci-
nated The drive to ‘mainstream’ Aboriginal Health Services may
have a subsequent impact on the health (including vaccination
rates) of people over the next decade, as older people lose access
to culturally safe health.
7. Conclusions
The workshop highlighted a substantial immunisation gap
between funded adult and infant vaccines, and explored the rea-
sons for this gap. These include the fact that adults are a mobile
population, sometimes with multiple health providers; the lack
of an adult immunisation register; lack of provider confidence in
elderly vaccination; ageism and value judgement in health care;
and lack of an evidence base in vaccine trials in the elderly. Table 1
summarises the key recommendations of the workshop. There is a
need for vaccine trials in frail elderly; for research on novel vaccine
technologies to overcome the reduced efficacy which results from
immunosenescence; for education of providers; elimination of
financial barriers; awareness in the community and amongst
healthcare workers of the high burden of vaccine preventable dis-
eases and the need to achieve high levels of vaccination coverage. A
whole of life immunisation register is key, and subsequent to this
workshop Australia has introduced such a register, the Australian
Immunisation Register. As the population continues to age, vacci-
nation for promotion of healthy ageing is an available and low cost
intervention which compares favourably to other accepted preven-
tion strategies in public health.
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